for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Rigel Pharmaceuticals, Inc.

RIGL.OQ

Latest Trade

--

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

--

 - 

--

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
--
Open
--
Volume
--
3M AVG Volume
34.12
Today's High
--
Today's Low
--
52 Week High
--
52 Week Low
--
Shares Out (MIL)
171.01
Market Cap (MIL)
393.31
Forward P/E
-24.47
Dividend (Yield %)
--

Next Event

Q4 2021 Rigel Pharmaceuticals Inc Earnings Release

Latest Developments

More

Rigel Pharmaceuticals Sees Q4 Revenue About $20.4 Mln

Rigel Sharpens Focus On Its Advanced Portfolio Opportunities

Rigel Reports Q3 2021 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The Company's research focuses on signaling pathways that are critical to disease mechanisms. The Company's product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its clinical program, Fostamatinib is being studied in a Phase III trial for the treatment of warm autoimmune hemolytic anemia (wAIHA). The Company's other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIP1) inhibitor program.

Industry

Business Services

Contact Info

1180 Veterans Blvd

SOUTH SAN FRANCISCO, CA

94080-1985

United States

+1.650.6241100

https://www.rigel.com/

Executive Leadership

Gary A. Lyons

Independent Chairman of the Board

Raul R. Rodriguez

President, Chief Executive Officer, Director

Dean L. Schorno

Chief Financial Officer, Executive Vice President

Dolly A. Vance

Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary

Wolfgang Dummer

Executive Vice President and Chief Medical Officer

Key Stats

1.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.1K

2020

0.1K

2021(E)

0.2K
EPS (USD)

2018

-0.440

2019

-0.400

2020

-0.180

2021(E)

-0.102
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.67
Price To Book (MRQ)
7.92
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
40.04
LT Debt To Equity (MRQ)
40.04
Return on Investment (TTM)
-13.43
Return on Equity (TTM)
-9.37

Latest News

Latest News

Eli Lilly in deal with Rigel to develop autoimmune therapy for up to $960 million

Eli Lilly will gain exclusive worldwide license to Rigel Pharmaceuticals Inc's autoimmune and inflammatory diseases treatment, including its lead candidate, R552, for potentially up to $960 million, the companies said on Thursday.

Eli lilly to pay up to $960 mln for Rigel's autoimmune disease therapy

Eli Lilly and Co will gain exclusive worldwide license to Rigel Pharmaceuticals Inc's autoimmune and inflammatory diseases treatment candidate for potentially up to $960 million, the companies said on Thursday.

NIH launches trial of Rigel drug for severe COVID-19

The U.S. National Institutes of Health on Thursday launched a clinical trial of fostamatinib, currently used to treat a blood platelet-destroying autoimmune disorder, in patients hospitalized with severe COVID-19, the disease caused by the novel coronavirus.

BRIEF-Rigel Announces Availability Of Tavlesse® In Europe

* RIGEL ANNOUNCES AVAILABILITY OF TAVLESSE® (FOSTAMATINIB DISODIUM HEXAHYDRATE) IN EUROPE

BRIEF-Rigel Reports First Quarter 2020 Financial Results

* RIGEL REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Rigel Reports Q4 Loss Per Share $0.10

* RIGEL REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up